Clinical Trials
15 trialsNCT05818683 2026-06-05
A Study of Pasritamig (JNJ-78278343) in Combination With Other Agents for Metastatic Prostate Cancer
Janssen Research & Development, LLC
Phase 1 Recruiting
NCT05997615 2026-06-04
AMX-500
Vir Biotechnology, Inc.
Phase 1 Recruiting
NCT07190300 2026-06-03
TulmiSTAR-02
Novartis
Phase 1/2 Recruiting
NCT07620041 2026-06-02
QLC5508 in Advanced Solid Tumors:: C-QTc, Pharmacokinetics (PK) Comparisons and Drug-drug Interaction
Qilu Pharmaceutical Co., Ltd.
Phase 1 Not yet recruiting
NCT05367440 2026-06-01
PETRANHA
AstraZeneca
Phase 1/2 Active not recruiting
NCT07617272 2026-06-01
PARIS-BIO
Region Stockholm
Phase 2 Recruiting
NCT07395804 2026-05-29
23146
Bayer
Recruiting
NCT07611110 2026-05-28
VECTRA-01
AstraZeneca
Phase 3 Recruiting
NCT04070209 2026-05-27
Management of Oligoprogressive Castration Resistant Prostate Cancer (PCS X)
Sir Mortimer B. Davis - Jewish General Hospital
Phase 2 Active not recruiting
NCT06120491 2026-05-27
EvoPAR-PR01
AstraZeneca
Phase 3 Active not recruiting
NCT05794906 2026-05-19
ARASTEP
Bayer
Phase 3 Active not recruiting
NCT06661122 2026-05-19
HAYATE
Bayer
Recruiting
NCT05348876 2026-05-18
A Study to Learn More About How Safe Darolutamide is and How Well it Works Under Real World Conditions When Taken in Addition to Standard Androgen Deprivation Therapy (ADT) in Indian Participants With High-risk Non-metastatic Castration-resistant Prostate Cancer (nmCRPC)
Bayer
Phase 4 Recruiting
NCT07244341 2026-05-15
A Study of Valemetostat (DS-3201b) in Combination With Darolutamide in Metastatic Castration Resistant Prostate Cancer (mCRPC)
Daiichi Sankyo
Phase 1 Recruiting
NCT07538843 2026-05-15
DARE
Bayer
Not yet recruiting